Roivant Sciences held a call to discuss their earnings for the first quarter of 2027.

Oct 5, 2026, 7:13 AM ETResultsRead the original at Benzinga

Good for ROIV

Roivant received an initial Moderna settlement payment and enrolled patients in a Phase 3 study, adding cash and progress to its drug program. A brepocitinib launch still depends on FDA action, and upcoming study results are not yet known.

ROIV · Roivant Sciences

AI read · Good for ROIV

The AI's read

The settlement payment gives Roivant more cash for its drug work. Study progress and a possible launch could create new sources of sales. The launch still depends on FDA action, and important study results are due later. Those benefits have not yet been proven.

Get alerts for ROIV

Follow Roivant Sciences (ROIV) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ROIV

Free on the App Store and Google Play, or on the web.